{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:25:36Z","timestamp":1788971136156,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.soc.2022.10.005","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T19:26:45Z","timestamp":1678822005000},"page":"279-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adrenocortical Carcinoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Lisa","family":"Kenney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marybeth","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2022.10.005_bib1","first-page":"635","article-title":"Current management options for recurrent adrenocortical carcinoma","volume":"6","author":"Glover","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"19","key":"10.1016\/j.soc.2022.10.005_bib2","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.3390\/cancers13195001","article-title":"Metabolic and endocrine toxicities of mitotane: a systematic review","volume":"13","author":"Bianchini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.soc.2022.10.005_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2006-0706","article-title":"Prognostic parameters of metastatic adrenocortical carcinoma","volume":"92","author":"Assi\u00e9","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.soc.2022.10.005_bib4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.soc.2022.10.005_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","article-title":"Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group","volume":"222","author":"Postlewait","year":"2016","journal-title":"J\u00a0Am Coll Surg"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2022.10.005_bib6","doi-asserted-by":"crossref","first-page":"A166","DOI":"10.1210\/jendso\/bvab048.336","article-title":"Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients","volume":"5","author":"Terzolo","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"5","key":"10.1016\/j.soc.2022.10.005_bib7","first-page":"387","article-title":"Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE)","volume":"48","author":"Nelson","year":"1949","journal-title":"Arch Pathol (Chic)"},{"issue":"4","key":"10.1016\/j.soc.2022.10.005_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-53-4-672","article-title":"Chemotherapy of adrenocortical cancer with o,p\u2032ddd","volume":"53","author":"Bergenstal","year":"1960","journal-title":"Ann Intern Med"},{"issue":"66","key":"10.1016\/j.soc.2022.10.005_bib9","doi-asserted-by":"crossref","first-page":"109924","DOI":"10.18632\/oncotarget.18968","article-title":"Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches","volume":"8","author":"Hescot","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.soc.2022.10.005_bib10","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1210\/jcem-23-9-918","article-title":"A\u00a0peripheral action of o,p' -ddd on steroid biotransformation","volume":"23","author":"Bradlow","year":"1963","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.soc.2022.10.005_bib11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1210\/jcem-36-4-730","article-title":"Effect of o,p'DDD on human adrenal steroid 11 beta-hydroxylation activity","volume":"36","author":"Brown","year":"1973","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.soc.2022.10.005_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6_suppl","key":"10.1016\/j.soc.2022.10.005_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2022.40.6_suppl.001","article-title":"First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: the adjuvo study","volume":"40","author":"Berruti","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.10.005_bib14","first-page":"62","article-title":"Role of mitotane in adrenocortical carcinoma - review and state of the art","volume":"14","author":"Paragliola","year":"2018","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.soc.2022.10.005_bib15","doi-asserted-by":"crossref","first-page":"9362108","DOI":"10.1155\/2018\/9362108","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"Biomed Res Int"},{"issue":"11","key":"10.1016\/j.soc.2022.10.005_bib16","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.10.005_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/biomedicines9020098","article-title":"The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma","volume":"9","author":"Karwacka","year":"2021","journal-title":"Biomedicines"},{"issue":"23","key":"10.1016\/j.soc.2022.10.005_bib18","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.soc.2022.10.005_bib19","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s10147-021-02021-8","article-title":"Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience","volume":"26","author":"Uchihara","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.10.005_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.soc.2022.10.005_bib21","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.soc.2022.10.005_bib22","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.soc.2022.10.005_bib23","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.soc.2022.10.005_bib24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.soc.2022.10.005_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.10.005_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.soc.2022.10.005_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.soc.2022.10.005_bib28","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.soc.2022.10.005_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.soc.2022.10.005_bib30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","article-title":"American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary","volume":"157","author":"Yip","year":"2022","journal-title":"JAMA Surg"},{"issue":"6","key":"10.1016\/j.soc.2022.10.005_bib31","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","article-title":"Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy","volume":"38","author":"Bednarski","year":"2014","journal-title":"World J Surg"},{"issue":"12","key":"10.1016\/j.soc.2022.10.005_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/biomedicines8120551","article-title":"Medical approaches in adrenocortical carcinoma","volume":"8","author":"Paragliola","year":"2020","journal-title":"Biomedicines"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:06:17Z","timestamp":1760961977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320722000850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1055320722000850"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2022.10.005","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adrenocortical Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2022.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}